title: Understanding the new pregnancy and lactation drug labeling.
abstract: Recent changes to the FDA's drug labeling rules clarify the risk of drugs for patients who are pregnant or lactating and remove A, B, C, D, and X as risk categories. Drugs are now categorized by risk for pregnancy, lactation, and women and men of reproductive potential. Risk summaries and clinical considerations in the new labeling can help prescribers and patients make informed decisions about medication use.
authors.affiliation: Elyse J. Watkins is an assistant professor in the PA program at High Point (N.C.) University. Mark Archambault is director of research and an associate professor at High Point University and the department editor of What's New in.... The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Elyse J
authors.initials: EJ
authors.lastname: Watkins
authors.forename: Mark
authors.initials: M
authors.lastname: Archambault
mesh_terms: D000328:Adult; D004348:Drug Labeling / Q000331:legislation & jurisprudence / Q000379:methods*; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced / Q000517:prevention & control*; D055553:Prescription Drugs / Q000009:adverse effects*; D012098:Reproduction / Q000187:drug effects*; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D055553:Prescription Drugs